Pharma deal analysis divides US FTC

The US Federal Trade Commission has approved Bristol-Myers Squibb’s acquisition of Celgene on a party-line vote, but both Democratic commissioners called for the agency to look more broadly at consolidation in the pharmaceutical industry.


Get unlimited access to all Global Competition Review content